Fig. 6

SLCP treatment partially preserved synaptophysin and PSD95 levels in the PFC and hippocampus of 5xFAD mice. Six- and 12-month-old 5xFAD and age-matched controls were treated with SLCP (100 mg/kg) for 2 months and then their brains were extracted, sectioned coronally at 40 μm, and stained with anti-synaptophysin and PSD95 antibodies. Images were taken using a fluorescent microscope at  4x0 (total magnification =  400x). a, b The vehicle-treated 5xFAD mice showed a decrease in synaptophysin fluorescent signals in the cortex, as well as the CA1, and CA3 areas of the hippocampus when compared to WT and SLCP-treated mice. e–h Western blot data from cortical and hippocampal tissue showed that synaptophysin was significantly reduced in vehicle-treated 5xFAD mice and that SLCP treatment prevented much of these losses. Scale bar= 100 μm and applicable to all other images. c, d Immunofluorescent intensity was decreased in vehicle-treated 5xFAD mice in comparison to WT mice, but SLCP treatments moderately preserved these levels in all three of the brain regions sampled. e, f and i, j Western blot data from cortical and hippocampal tissue showed that PSD95 levels were significantly reduced in vehicle-treated 5xFAD mice and that SLCP treatment partially preserved these levels. Scale bar indicates 100 μm and applicable to all images. *p < 0.05, **p < 0.01 in comparison to WT + vehicle, 5xFAD + SLCP, and WT + SLCP. Scale bar = 100 μm for all images.